L. Merino

发表

Development of a leakage monitoring system in isolated limb perfusion with portable gamma camera

F. J. Gómez, A. Agudo Martínez, L. de la Cruz Merino, 2020 .

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

D. Schadendorf, V. Sondak, P. Ascierto, 2022, The Lancet.

SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma

M. P. Pulla, M. Muñoz, A. R. Domínguez, 2010 .

LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial

D. Schadendorf, V. Sondak, P. Ascierto, 2021, Annals of Oncology.

43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial

S. Swain, S. Sarkar, S. Delaloge, 2021 .

SEOM clinical guidelines for the treatment of Hodgkins lymphoma

M. P. Pulla, M. Muñoz, D. Casado, 2010 .

Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA – N 2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy †

Ronald, Ramalingam, Igor, 2015 .

961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

A. Arance, Helena Escuin-Ordinas, C. Robert, 2021, Journal for ImmunoTherapy of Cancer.

Clinical guideline SEOM: cancer of unknown primary site.

R. Martin, P. García, A. Palomo, 2014 .

Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib

Jose A. Rodriguez, S. Martínez, L. Merino, 2016 .

Abstract P5-15-03: nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial

A. Schneeweiss, N. Harbeck, J. Cortes, 2017 .

LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004

A. Carneiro, G. Long, L. Ny, 2020 .

1143P Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials

C. Tebé, E. Espinosa, A. Joshua, 2020 .

A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma and central nervous system (CNS) metastases (mets).

R. Dummer, H. Tawbi, P. Queirolo, 2020 .

Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study.

P. Ascierto, P. Queirolo, R. Gutzmer, 2020 .

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

I. Zalaudek, A. Hauschild, R. Dummer, 2017, European journal of cancer.

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.

L. Zelek, A. Ballestrero, L. Fallowfield, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

P. Ascierto, J. Larkin, M. Mandalà, 2020 .

SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

Mafalda Oliveira, S. López-Tarruella Cobo, J. Gavilá Gregori, 2019, Clinical and Translational Oncology.

The Prevalence and Nature of Cancer-Related Neuropathic Pain in Out-Patient Services in Spain

V. López-Gómez, J. Sepúlveda, C. Garzón-Rodríguez, 2013 .

Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.

R. Houot, J. Briones, C. Flowers, 2017 .